Wrongfully accused: XXXX use in @entity712 .

@entity1 @entity712 @entity6 @entity1017 @entity164 @entity2449
Evaluation of: Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. @entity2449 use and mortality in ambulatory @entity1 with @entity6 and @entity712 . Circ. Heart Fail. 4(1), 53-58 (2010). @entity2449 has long been the cornerstone of therapy for glycemic control in @entity1 with @entity164 2 @entity6 worldwide. It is recommended as first-line therapy by all major @entity6 clinical practice guidelines owing to its efficacy, favorable tolerability profile and beneficial effects in limiting @entity1017 . Moreover, @entity2449 is the only oral anthyperglycemic agent shown in randomized controlled trials to reduce mortality in newly diagnosed @entity1 with @entity164 2 @entity6 . However, the use of @entity2449 has not been without controversy, in particular in @entity1 with @entity712 . This article will review a recent observational study by Aguilar et al. published in Circulation - Heart Failure that reported improved outcomes associated with @entity2449 therapy in @entity1 with @entity6 and @entity712 .
